Strattera Articles
Double dose of woes for Eli Lilly, as it drops Ph III AD drug semagacestat and FDA panel could say no to expanding use of Cymbalta
18 August 2010
Court rules against Eli Lilly in patent dispute over Strattera, but drug major will appeal
16 August 2010
ADHD drug ban rejected by Australia
19 January 2009
FDA clears Lilly's Strattera in ADHD maintenance
19 May 2008
EMEA denies "suicide rating for all drugs" claim
18 February 2008
Lilly's 4th qtr recovers from Zyprexa settlement
4 February 2008
Eli lilly sees 3rd qtr net income climb 6% as sales jump 19% to $4.6B, raises full-year guidance
29 October 2007
Medicines Australia welcomes govt boost
14 May 2007
Lilly's Strattera added to Australian PBS
30 April 2007
Lilly's 1st-qtr 2007 earnings drop 39%
23 April 2007
Lilly's income down 81%, but shares up 1.5%
12 February 2007
Strattera helps patients with reading disorders
6 November 2006
Lilly swings to 2nd-qtr 2006 EPS of $0.76
31 July 2006
Eli Lilly profit up 6% in 1st-qtr 2006
1 May 2006
Lilly swings to 4th-qtr 2005 profit
6 February 2006
Strattera supreme in ADHD market; brand stimulants slump
22 August 2005
Lilly swings to loss in 2nd qtr on settlement
1 August 2005
Legal group puts US FDA Rx ad reg under scrutiny
4 July 2005
Stock Commentary - New York
6 June 2005
Strattera: emotional benefit in women
6 June 2005
EMEA warning over SSRIs, SNRIs in children
26 April 2005
Stock Commentary - New York
25 April 2005
Eli Lilly reports 84% income rise in 1st qtr
25 April 2005
Scotland OKs Femara, rejects other drugs
14 March 2005
BMJ turns over confidential documents to FDA on Lilly's Prozac
10 January 2005
Lilly adds liver warning to Strattera label
10 January 2005
Stock Commentary - New York
10 January 2005
Eli Lilly's income up 6% for 3rd-qtr 2004
1 November 2004
Lilly's Strattera available in UK
19 July 2004
Lilly's Stratterra approved in the UK for ADHD
14 June 2004
Strong 2003 sales for Lilly but profits flat
9 February 2004
New Chemical Entities in 2003
19 January 2004
Shire beats expectations in third quarter as ADHD product sales soar
17 November 2003
Launches hit Lilly's profits, sales strong
27 October 2003
Eli Lilly's Strattera gains 16.3% of new Rxs in the USA
27 October 2003
Zyprexa lifts Eli Lilly above estimates
4 August 2003
Underlying growth beats forecasts at Lilly
28 April 2003
2002's crop of new product launches backs up R&D fears
10 February 2003
Lilly launches Strattera for ADHD in USA
20 January 2003
Lilly
19 August 2002
Showing 1-53 of 53 articles
- 1
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
